the tape · 2026-10-07BULL▼ -19.1%GLND▼ -9.7%GPRO▼ -7.6%MSTR▼ -6.8%CAT▼ -5.7%NBIS▼ -5.1%MU▲ +4.1%COIN▼ -3.9%ASTS▼ -3.9%VST▲ +3.9%SMCI▲ +3.4%AVAV▼ -3.3%GEV▼ -3.1%ARM▼ -2.7%LLY▲ +2.7%RDDT▲ +2.5%SPCX▼ -2.5%NEM▼ -2.4%META▼ -2.4%HPE▲ +2.3%

LLY

Eli Lilly · 40 big moves · 1 videos · since May 2026
1,2931,2011,188.72Jul 15Oct 07
From the desk · Aug 26, 2026

LLY slid 3.6 percent today, and the culprit is a study that was supposed to help Lilly — not hurt it. New cost-saving data for Zepbound, the company's obesity drug, showed meaningful reductions in downstream medical expenses. Problem: the study doesn't include what Zepbound actually costs. That's a critical gap when you're pitching payers — insurers and pharmacy benefit managers who will absolutely net the drug's price against any gross medical savings before agreeing to cover it. When you run that fuller math, the case gets harder. Ken Griffin nearly quadrupled his Lilly stake in the second quarter, which suggests conviction in the long thesis. The Alzheimer's diagnostic news today was genuinely good. But Zepbound's reimbursement story still has a hole in it, and the market noticed.

Every move of 1.5% or more
2026-10-07 · Yahoo Finance

+2.7% — Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets

T+1 — pendingT+5 — pendingT+20 — pending
2026-09-30 · Yahoo Finance

-2.3% — Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduct

T+1 -0.6%T+5 +2.7%T+20 — pending
2026-09-24 · Yahoo Finance

+2.7% — Eli Lilly (LLY) Stock Is Up, What You Need To Know

T+1 +0.1%T+5 -2.7%T+20 — pending
2026-09-23 · Yahoo Finance

-1.6% — Could Retatrutide Be Worth $10 Billion to Eli Lilly?

T+1 +2.7%T+5 +0.5%T+20 — pending
2026-09-14 · Yahoo Finance

+2.0% — Why the Market Dipped But Eli Lilly (LLY) Gained Today

T+1 -0.2%T+5 +2.3%T+20 — pending
2026-09-08 · Yahoo Finance

-2.2% — Here's Why Eli Lilly (LLY) Fell More Than Broader Market

T+1 +0.0%T+5 +1.1%T+20 +3.0%
2026-08-31 · Yahoo Finance

-1.5% — Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors.

T+1 +0.3%T+5 -2.8%T+20 +2.4%
2026-08-26 · Yahoo Finance

-3.6% — Eli Lilly Clears Big Hurdle in Alzheimer's Fight

T+1 -1.1%T+5 -2.5%T+20 -0.6%
2026-08-20 · no single source

-2.8% — Moved with the tape — no single reported reason that day.

T+1 +0.9%T+5 -5.5%T+20 -7.4%
2026-08-19 · Benzinga

+4.5% — Netflix, Eli Lilly, Elanco Animal Health And More Stock On CNBC’s ‘Final Trades’

T+1 -2.8%T+5 -7.1%T+20 -10.0%
2026-08-18 · SeekingAlpha

+3.6% — OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech

T+1 +4.5%T+5 +0.6%T+20 -7.2%
2026-08-14 · Yahoo

-2.4% — 5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call

T+1 +0.3%T+5 +6.4%T+20 -3.5%
2026-08-10 · Yahoo

+3.9% — Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

T+1 -1.4%T+5 -4.0%T+20 -8.8%
2026-08-06 · SeekingAlpha

+1.9% — Eli Lilly: Fine Q2 2026 Results, But Alertness Required

T+1 -0.5%T+5 +1.4%T+20 -2.7%
2026-08-05 · Yahoo

+4.9% — Eli Lilly and Co (LLY) (Q2 2026) Earnings Call Highlights: Revenue Surges 48% on Zepbound and ...

T+1 +1.9%T+5 +4.3%T+20 -0.8%
2026-08-03 · Yahoo

-2.4% — Eli Lilly (LLY) Wins FDA Breakthrough Tag For Olomorasib, Backs $70 Million Raise

T+1 -0.5%T+5 +9.9%T+20 +3.2%
2026-07-30 · Yahoo

-4.5% — Lilly Boosts Diabetes and Obesity Capacity With $750 Million Deal

T+1 -0.5%T+5 +3.2%T+20 +1.8%
2026-07-28 · Yahoo

+1.9% — Does Eli Lilly Stock Actually Diversify Your Portfolio?

T+1 -0.9%T+5 -8.6%T+20 +1.1%
2026-07-23 · Yahoo

+2.0% — There's A Hidden Gem In Eli Lilly's Weight-Loss News — And It Could Slam Compounders

T+1 +0.9%T+5 -2.6%T+20 +4.9%
2026-07-21 · Yahoo

+2.5% — "Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What Tha

T+1 -1.1%T+5 +3.8%T+20 +4.3%
2026-07-20 · Yahoo

-2.7% — Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?

T+1 +2.5%T+5 +4.4%T+20 +3.2%
2026-07-14 · Yahoo

-2.5% — Eli Lilly Wins Full FDA Approval for Selpercatinib in Solid Tumors

T+1 +0.4%T+5 +2.0%T+20 +5.4%
2026-07-10 · Benzinga

-2.3% — B of A Securities Maintains Buy on Eli Lilly, Raises Price Target to $1334

T+1 -0.6%T+5 -0.8%T+20 -0.2%
2026-07-08 · Yahoo

-1.6% — Is It Too Late to Buy Eli Lilly?

T+1 +0.1%T+5 -4.9%T+20 -3.8%
2026-07-07 · Yahoo

+3.0% — Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 B

T+1 -1.6%T+5 -6.7%T+20 -9.7%
2026-07-02 · Yahoo

+1.9% — Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?

T+1 -1.1%T+5 -2.1%T+20 -5.4%
2026-06-30 · Yahoo

-2.5% — Medicare GLP-1 Bridge Program Will Pay for Novo, Lilly Drugs

T+1 -0.6%T+5 +1.4%T+20 +0.9%
2026-06-29 · Yahoo

+1.8% — Should You Chase The Breakout In Eli Lilly Stock?

T+1 -2.5%T+5 +0.5%T+20 -0.8%
2026-06-26 · Yahoo

+7.1% — Lilly, J&J and AbbVie Hit New Highs  ▶ we covered it

T+1 +1.8%T+5 -0.7%T+20 -0.9%
2026-06-12 · no single source

-2.4% — Moved with the tape — no single reported reason that day.

T+1 -0.3%T+5 -2.7%T+20 +1.7%
2026-06-11 · no single source

+2.2% — Moved with the tape — no single reported reason that day.

T+1 -2.4%T+5 -5.4%T+20 +1.8%
2026-06-08 · no single source

+1.6% — Moved with the tape — no single reported reason that day.

T+1 -0.4%T+5 -1.7%T+20 +5.8%
2026-06-04 · no single source

+4.3% — Moved with the tape — no single reported reason that day.

T+1 +0.5%T+5 +3.2%T+20 +6.6%
2026-06-02 · no single source

-1.7% — Moved with the tape — no single reported reason that day.

T+1 +1.4%T+5 +7.6%T+20 +12.0%
2026-06-01 · no single source

-2.1% — Moved with the tape — no single reported reason that day.

T+1 -1.7%T+5 +6.2%T+20 +10.8%
2026-05-29 · no single source

-1.9% — Moved with the tape — no single reported reason that day.

T+1 -2.1%T+5 +2.4%T+20 +11.3%
2026-05-28 · no single source

+4.1% — Moved with the tape — no single reported reason that day.

T+1 -1.9%T+5 -0.1%T+20 +7.2%
2026-05-27 · Yahoo

+1.7% — Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?

T+1 +4.1%T+5 -0.4%T+20 +4.1%
2026-05-22 · no single source

+2.2% — Moved with the tape — no single reported reason that day.

T+1 -0.0%T+5 +1.6%T+20 +4.0%
2026-05-21 · no single source

+2.2% — Moved with the tape — no single reported reason that day.

T+1 +2.2%T+5 +6.1%T+20 +5.8%

The brief, in your inbox

One email every market morning. What moved, why, and what happened after.